ACHR/WS Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeValuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- —
- P/S (TTM)
- —
- EV/EBITDA
- —
Profitability & growth
- ROE (TTM)
- 0.0%
- Operating margin
- 0.0%
- Revenue growth YoY
- 0.0%
- Dividend yield
- —
- Beta
- —
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
22 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About ACHR-WS
Company profileAchieve Life Sciences, Inc. (Ticker: ACHR-WS) is a forward-thinking clinical-stage biopharmaceutical company dedicated to developing innovative therapies for smoking cessation and nicotine addiction, primarily focusing on its lead candidate, cytisine. By targeting a critical public health issue, Achieve aims to offer effective alternatives to conventional cessation methods, aligning with the growing demand for superior nicotine replacement therapies. The company's strategic approach emphasizes enhancing patient outcomes and leveraging partnerships, positioning Achieve to broaden its product…
Company profile
- HQ
- NONE
- Latest quarter
- —
Educational content · Not investment advice or recommendations
We're educators, not advisors. Your decisions are your own. Disclaimer
I'm your AI thinking companion for the markets — I can help you explore and learn, but I'm not a financial advisor. Everything here is educational. Disclaimer